PhysioCue

PhysioCue is a digital health and therapy device development company that has developed a non-invasive hypertension therapy device. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with anti-hypertensive drugs.

We have manufactured our devices and delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices.

PhysioCue has manufactured hypertension therapy and migraine and headache therapy devices; we've delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhyaioCue also launched our Migraine pain monitoring mobile app: MigraineCue. MigraineCue is able to monitor an individual's migraines and headaches daily.

We do not intend to manufacture, distribute, or sell our devices. Instead, our go-to-market strategy uses strategic regional partnerships to accomplish these steps. We are having a strategic partnership and licensing discussions with major medical suppliers, retail distributors, and health insurers in the DNR Corp. in Indonesia, Saudi Arabia, and China.

Hypertension device markets are enormous in size and potential. More than 30% of the world population has hypertension and the consequent cost of the individual and the society are mounting, $5T/year direct and indirect. Furthermore, hypertension is known as a silent killer since it is responsible for most of the mortality and paramount diseases of cardiovascular, kidney, bone, vision, and even sexual problems. Drugs are expensive, averaging more than $150 per month, and can have severe side-effects that cause many patients to seek alternative treatments—or none at all.

PhysioCue therapy devices are non-invasive, with no pain, immediate effect, safe, easy to use, and have none of the side effects associated with drugs. PhysioCue therapy devices are all; non-invasive, with no pain, no side-effect, immediate effect, cost-effective, easy to use, and user’s friendly device.

High blood pressure is a very big risk for COVID-19, The Hypertension device markets are very important globally, especially during these times of duress where many people are at home. Our devices can help people and save lives.

Large pharmaceutical companies, including Pfizer, Merck, AstraZeneca, Novartis, Bristol Myers Squibb, Aventis, GSK and Bayer dominate the market for hypertension and migraine and headache treatment with various drugs but drugs are expensive, averaging more than $150 per month, and can have severe side-effects that cause many patients to seek alternative treatments—or none at all. “Medical therapy devices” include Resperate (www.resperate.com), a biofeedback system that trains people to breathe properly, reducing their high blood pressure over 8 weeks. CVRx (www.cvrx.com) has a surgically implanted device, this solution is invasive, prohibitively expensive, and only appeals to Stage 3 hypertensives, which is about 3% of the market.

PhysioCue therapy devices are all; non-invasive, with no pain, no side-effect, immediate effect, cost-effective, easy to use, and user’s friendly device. On the other hand, competitors require a surgical implant or limited efficacy of the treatment effect.

We sold 5000 units,

Pricing
• Current manufacturing cost in China: ~$120,
• Target FOB ~$80,
• MSRP from $299 - $350.
• Equipment leasing and/or annual service plan for recurring revenues

Sales through indirect distribution and white-labeling
• QVC & HSN distribution for current sub -$299 product with limited claims
• GSK, J&J, Medtronic and others, OSIM, DNR, Century Medical etc.

We are having strategic partnerships and licensing discussions with major medical suppliers, retail distributors. 5,000 units of first version hypertension therapy devices were built and marketed. Based on the feedback, newer version of multi-products ready (Hypertension therapy device, Headache migraine therapy device, bio-sensor module) & Mobile App (Migraine App, and BP monitoring App). Multi devices and mobile app.

Use of Funds:
Certification for UL, CE, FDA 510 (K) Approval, Additional Clinical trials
Dedicated Sales & Marketing, Develop EU & Asia distribution channel
Independent database & software interface / Migraine Mobile App / BP Monitoring App
Final Stage R&D for Model Q3 & Q4
Legal expenses relating to additional IP & Licensing
Complete mass production capabilities & Operations Expenses

The Hypertension and Migraine/headache device market are very large and very important globally, PhysioCue received the $3.5M investment from multination. Tested and received excellent feedback from users. PhysioCue has a great team with excellent medical advisory board. Active discussion with multiple global firms from partnerships.

Large pharmaceutical companies, including Pfizer, Merck, AstraZeneca, Novartis, Bristol Myers Squibb, Aventis, GSK and Bayer dominate the market for hypertension and migraine and headache treatment with various drugs but drugs are expensive, averaging more than $150 per month, and can have severe side-effects that cause many patients to seek alternative treatments—or none at all. “Medical therapy devices” include Resperate (www.resperate.com), a biofeedback system that trains people to breathe properly, reducing their high blood pressure over 8 weeks. CVRx (www.cvrx.com) has a surgically implanted device, this solution is invasive, prohibitively expensive, and only appeals to Stage 3 hypertensives, which is about 3% of the market.

Not yet,

PhysioCue has been selected for the 4th World Intelligent Congress
PhysioCue's MigraineCue selected top 10 Patient Monitoring Solution Providers.
PhysioCue received the RESI received the Innovation Challenge 3rd Award
PhysioCue received the Innovation Award from FTZ Overseas Talents Innovation Conference in Shanghai China
PhysioCue received 2nd Award from InnoSTARTS competition in Shenyang, China
And more...